A study published in Clinical Cancer Research indicates that a blood-based test could assist in guiding treatment decisions for a specific group of women aged 70 and over with estrogen receptor-positive breast cancer. These women were considering endocrine therapy as a primary treatment, potentially foregoing surgery and radiation.
The research aimed to personalize care, recognizing that not all patients require identical treatments based solely on their diagnosis.
Understanding the Approach
Researchers analyzed blood samples for circulating tumor DNA (ctDNA), which are genetic fragments shed by cancer cells. The objective was to determine if the presence or absence of these fragments could identify patients unlikely to respond to endocrine therapy alone.
Key Findings
- Patients with negative ctDNA results, either at the start of treatment or after beginning endocrine therapy, showed a higher likelihood of stable disease or tumor shrinkage. For this group, additional treatments like surgery and radiation, which carry potential side effects, might not significantly improve outcomes.
- Conversely, patients whose ctDNA remained positive after endocrine therapy were more likely to experience tumor growth while on medication. This suggests that surgery or other treatments may be necessary for tumor control in these cases.
The study focused on identifying an early decision window to help doctors determine which patients are less likely to respond to hormone therapy alone, rather than assessing the overall effectiveness of treatments.
Enhancing Patient Convenience
The use of blood tests for ctDNA allowed patients to participate without frequent hospital visits, with samples often collected from their homes. This approach aimed to reduce travel burden and facilitated patient enrollment from various UPMC Hillman network oncology sites.
Patient and Caregiver Perspectives
Feedback from patients and caregivers was also incorporated into the study.
Over 80% of patients reported that ctDNA test results could enhance their understanding of treatment decisions, particularly during the initial 6 to 12 months.
Caregivers noted that supporting loved ones often required prioritizing caregiving responsibilities. Researchers emphasized that a home-based monitoring option could be a significant benefit for caregivers and highlighted the importance of patient education and shared decision-making.
Limitations
Researchers caution that this was a small study involving fewer than 50 patients, and the findings are not yet applicable to standard clinical practices. Larger studies are required before this approach can be routinely used.